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The impact of free trial acceptance on
demand for alternative nicotine products:
evidence from experimental auctions
Matthew C. Rousu1, Richard J. O’Connor2*, Maansi Bansal-Travers2, James M. Pitcavage3 and James F. Thrasher4

Abstract
Objectives: This study explored the relationship between product trials and consumer demand for alternative
nicotine products (ANP).
Methods: An experimental auction was conducted with 258 adult smokers, wherein participants were randomly
assigned to one of four experimental conditions. The participants received the opportunity to try, but did not have
to accept, one of three relatively novel ST products (i.e., snus, dissolvable tobacco, or medicinal nicotine), or they
were placed into a control group (i.e., no trial). All the participants then bid on all three of these products, as well
as on cigarettes. We assessed interest in using ANP based on both trial of the product and bids placed for the
products in the experimental auction.
Results: Fewer smokers were willing to try snus (44 %) than dissolvable tobacco (64 %) or medicine nicotine (68 %).
For snus, we find modest evidence suggesting that willingness to try is associated with greater demand for the
product. For dissolvable tobacco or medicinal nicotine, we find no evidence that those who accept the product
trial have higher demand for the product.
Conclusions: Free trials of a novel ANP were not strongly associated with product demand, as assessed by
willingness to pay. Given the debate over the potential for ANP to reduce the harm from smoking, these results are
important in understanding the impact of free trial offers on adoption of ST product as a strategy to reduce harm
from tobacco use.
Keywords: Tobacco, Smokeless, Experimental auction, Auction, Demand, Smokeless tobacco, Trials, Product trials

Introduction
Since the 1990s, tobacco products modified to potentially reduce health risks have been marketed to
smokers. One class of such products is a form of smokeless tobacco (ST) modeled on Swedish snus, which is
processed to reduce tobacco-specific nitrosamines and
other toxicants [1] and has been linked to reduced
smoking rates and cancer mortality [2–4]. Snus products
were first introduced in the US market by Swedish
Match (Revel and General Snus), and later by RJ Reynolds
(Camel Snus), UST (Skoal Snus), and Philip Morris
(Taboka, Marlboro Snus). Adoption of snus by US
* Correspondence: Richard.Oconnor@roswellpark.org
2
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smokers has been low [5] despite the fact that overall ST
product use appears to be increasing [6].
Other novel ST products have also been introduced
into the US market. Lozenge-like products made with
powdered tobacco have also been marketed to smokers,
including Ariva and Stonewall (Star Scientific). The
market in such “dissolvable” tobacco products was later
expanded by RJ Reynolds, which introduced Camel
Orbs, Sticks, and Strips, and Philip Morris, which testmarketed Marlboro and Skoal Sticks. The FDA’s Tobacco Products Scientific Advisory Committee (TPSAC)
reviewed the health impact of dissolvable products, finding that while exclusive use of dissolvable tobacco products was likely less hazardous than cigarette smoking,
uncertainties on patterns of use and marketing prohibited firm conclusions on overall public health impact [7].
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Despite survey evidence suggesting significant demand
among smokers for products promoted as less harmful,
available data suggest few smokers have adopted these
products. Males appeared to be more likely to have tried
dissolvable products in test markets [8]. Perhaps, in response to low demand, most dissolvables had been withdrawn from the market as of 2014.
One way to gauge interest in ST products directly is
by offering free trials. This is a common marketing approach designed to reduce innovation resistance by addressing potential cost and risk barriers [9]. Tobacco
companies have offered free trials as a way of encouraging ST use [10–12], which is consistent with their past
practice of free cigarette giveaways as a promotional
strategy [13]. Although the Family Smoking Prevention
and Tobacco Control Act of 2009 now prohibits free
samples of cigarettes, offering free samples of ST products is allowed.
Experimental economic methods estimate demand by
encouraging people to reveal their true valuation of different products ([14, 15]. A key benefit of experimental
auctions comes from placing consumers in a real auction, with winners and losers, and where the winners
pay for products. This prevents hypothetical bias in surveys and “willingness to pay” studies, where there are no
financial consequences to self-reported desires for a
product. The experimental auction can be designed so it
accurately elicits the demand curve for products [16]
and has been employed in recent years to examine issues
related to tobacco products. Monchuk et al. [17] examined the value of nicotine in tobacco products using experimental auctions. Thrasher et al. [18, 19] and Rousu
and Thrasher [20] used experimental auctions to examine the demand-reducing impact of health warning labels containing prominent pictorial imagery illustrating
the consequences of smoking. Rousu et al. [21] used experimental auctions to examine the demand for potentially reduced exposure products (PREPs) relative to
conventional cigarettes.
In this paper, we use experimental auctions to explore
the link between willingness to accept a free trial of ST
and demand for ST. All participants in the auction were
smokers but not regular ST users. The participants were
offered trials of three alternative nicotine products
(ANP): Camel Snus, Ariva, Nicorette, or nothing (in the
control group).1 These products were selected because
they are marketed to smokers (as opposed to ST users)
and had been previously studied among smokers [22–24].
All participants then bid on cigarettes and these ANP in
an experimental auction, where the bid represents a participant’s demand for one package of the item being bid
upon. Results will provide insight into how well product
trials translate into demand for ANP. Results will also provide evidence whether participants are equally likely to

Page 2 of 9

accept a trial of any ANP. These results are important for
public health officials who want to understand whether
product trials increase demand for ANP.

Methods
Participant recruitment and sample size

The study protocol was approved by the IRBs at the
University of South Carolina, Roswell Park Cancer
Institute, and Geisinger Medical Center. Participants
were recruited by radio ads, newspaper ads, and flyers
in Buffalo NY, Columbia SC, and Selinsgrove PA. These
sites were chosen because they differ substantially in
prevalence of ST use, cigarette taxes, and clean indoor
air policies. Eligible study participants were 18 years old
and older, currently smoked, were not currently using
nicotine replacement or ST products, and had no major
medical issues that would warrant exclusion. We excluded current ST users, as we were primarily interested
in the interest of current smokers in potential alternatives to cigarettes. So, those with current or regular ST
use would likely have different (preformed) opinions
about the products relative to more naïve smokers.
Participants were paid US$50 for their participation in
the 1-h sessions. Auctions were conducted with eight to
sixteen participants at a time with a total of 258 smokers
participating between November 2010 and November
2011. This analysis uses a subset of the data reported in
Rousu et al. [25], which focused on the impact of information on ANP choices more than the impact of product trials.
The products

Participants placed separate auction bids for four separate products. Participants bid on three cigarette alternatives: Camel Snus, Ariva Dissolvable Tobacco, and
Nicorette Mini-lozenge. These products were chosen to
cover three distinct product styles (pouched ST, dissolvable tobacco, and medicinal nicotine, respectively) available in the open market. Participants also bid on
Marlboro brand cigarettes, either the red, menthol, gold
(light), or menthol gold (light) variety, depending on
their individual preference. The fact that participants
were able to bid on the most popular brand family in
one of four product classes allows comparisons of bids
on ST products to bids for cigarettes.2
Experimental conditions

We sought to assess demand for the three ANP, relative
to cigarettes, under alternative treatments. Treatment
assignment was at the group level—all participants at a
given auction session received the same treatment to facilitate the auction protocol. Table 1 shows the treatments and the distribution of participants per treatment
in each site. Participants (except for those in the control
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Table 1 Demographic characteristics–overall and by treatmenta
Overall
(N = 258)

Control
(N = 62)

Snus trial
(N = 64)

Nicorette trial
(N = 67)

Ariva trial
(N = 65)

Offered and tried the
ST product (N = 115)

Offered but did not try
the ST product (N = 81)

Race–white

65 %

66 %

67 %

66 %

60 %

68 %

59 %

Race–black

28 %

31 %

23 %

27 %

32 %

27 %

28 %

Race–other

7%

3%

9%

7%

8%

5%

12 %

Age–under 30 yearsb

38 %

27 %

36 %

39 %

51 %

44 %

38 %

Age–30 to 50 years

38 %

35 %

41 %

36 %

38 %

39 %

37 %

b

Age–over 50 years

24 %

37 %

23 %

25 %

11 %

17 %

25 %

Female

44 %

39 %

41 %

51 %

45 %

38 %c

55 %

Income–below 30 K

57 %

56 %

63 %

49 %

58 %

54 %

60 %

Income–between 30 and 60 K

10 %

19 %

09 %

10 %

11 %

14 %

14 %

Income–over 60 K

15 %

10 %

11 %

13 %

17 %

10 %

10 %

Income–chose not to reveal

18 %

15 %

17 %

27 %

14 %

22 %

16 %

Moderately or very worried
about future quality of life

61 %

61 %

59 %

64 %

58 %

62 %

59 %

Prior smokeless tobacco use

43 %

39 %

50 %

43 %

38 %

55 %c

28 %

Observations–NY

36 %

39 %

33 %

36 %

38 %

38 %

30 %

Observations–SC

34 %

35 %

36 %

37 %

29 %

32 %

37 %

Observations–PA

29 %

26 %

31 %

27 %

32 %

30 %

31 %

a

Auctions conducted from November 2010–November 2011
b
The only demographic characteristics that differed across treatment groups at a significance level of 0.05 or less was the over 50 age group (p < 0.01). No other
differences in demographic characteristics were found to be significant at the 5 % level using a chi-squared test
c
The only demographic or background characteristics where there were statistically significant differences in the percentage who tried ST products was for
females (p < 0.05) and for those who had used smokeless tobacco at some point in the past (p < 0.01)

group) were offered the opportunity to try either Camel
Snus, Ariva, or Nicorette, depending on assigned condition (see Table 1). We asked the participants if they
would like to try the product but did not require trial to
continue in the study. Participants who tried the product
were instructed to place the product in their mouth
(with supplemental instructions for snus to place between upper lip and gum), to not chew the product, and
the leave it in the mouth for up to 5 min. We asked the
participants who tried the products to keep their reactions to themselves until after the experiment ended.
For analytic purposes, we distinguished those who declined the trial offer from those who accepted it (since
the non-triers would bias the effect toward the null).
While participants placed a separate bid on each of the
four products, only one product was chosen as the binding product (i.e., the product that would actually be auctioned). This product was selected after all bidding by a
random draw to ensure participants would not decrease
their bids due to thinking they might win more than one
tobacco product [26].
Experimental design

Data were collected using the random nth price auction
mechanism (Shogren et al. [27], in which participants
are initially given enough money to compensate for their

time and to provide them with more than enough
money to pay the “winning” price for the product of
interest.3 Participants are told that this auction is different from other auctions in that they can only bid
once (on a product), and it is in their best interest to
submit a bid equal to the full price they would pay
for the product. Once all bids are collected, bids are
sorted from highest to lowest. After eliminating the
highest bid, one bid is then selected randomly. The
(n-1) participants that bid more than this randomly
selected price purchase the product, paying the price
of the selected nth highest bid; the participants who
bid less than (and the participant whose bid is equal
to) the nth highest bid do not purchase the product.
In this mechanism, a participant will not pay more
than their submitted bid for the product. This auction
is “demand revealing” in that it is in a participant’s
best interest to bid his or her true value (demand)
for the product because the amount the auction winners pay is determined by another subject’s bid, not
their bid. Someone who bids higher than her true
value for the product could end up paying more than
that true value, while someone who bids lower than
her true value may miss out on a profitable purchase
if the randomly selected binding price is less than her
true value but higher than the bid she submitted.
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Procedures

After participants arrived and signed a consent form,
they filled out a brief survey on their tobacco use history
(Step 1). Next (Step 2), participants received a detailed
explanation of the auction mechanism (both orally and
in writing), emphasizing that it was in their best interest
to bid their true value for the products. Participants also
took a quiz to ensure they understood the auction procedures. The monitor went through the answers to the
quiz questions with participants. Next, the participants
participated in a practice auction for two candy bars
(Step 3) that demonstrated the real procedures by having
participants place bids for different candy bars in different rounds, including random selection of the binding
product. The detailed explanations, the quiz, and the
practice auction helped ensure that all participants
understood the procedures. In Step 4, participants received their randomly assigned treatment (trial of Camel
Snus, Ariva, Nicorette, or no trial). Then (Step 5), the
participants placed separate, private bids on each of the
four products. As it was impractical to randomize the
order of bidding within and across treatments, participants in all treatments always placed their first bid on
the Snus, their second bid on the Ariva, their third bid
on the Nicorette, and their final bid on the cigarettes.
After all four bids were submitted, a random draw was
conducted to determine which product was the binding
product, followed by a random draw to determine the
nth price (Step 6). This determined who won products,
which product, and how much the winners would pay.
Finally (Step 7), participants filled out a post-auction
questionnaire, winners exchanged money for their product, and the experiment ended. The post-auction questionnaire included an item that asked “How much do
you think the Camel Snus you bid on in the auction
would cost in a local store?”. There were three similar
questions for cigarettes, Ariva, and Nicorette.
Analysis

To examine the impact of demographic- and tobaccorelated characteristics on product trial, along with the
product being offered to participants, we used probit
models. If participant i tried the product, we define this
as Di = 1. To examine the impact, the product and
demographic and tobacco-related characteristics have on
the probability of a accepting a product trial, a probit
model is used and is shown in the following equation:
ProbðDi ¼ 1Þ ¼ f ðα þ δ 0 Li þ βX i þ γ 0 C i þ εi Þ

ð1Þ

Where α is an intercept term; Li is a dummy variable
that represents the ST product a person was offered and
δ’ is the associated coefficient; Xi is a vector that represents the demographic characteristics of participant i

and β’ is the associated coefficient vector; Ci is a vector
that represents the tobacco-related characteristics of participant i and γ’ is the associated coefficient vector, and
εi is the error term. To examine the possible impact of
product trials and participant characteristics on demand
for ST, we estimated a random effects regression model
with the following equation:
BIDit ¼ αi þ μ’Pi þ β’X i þ δ’Li þ π’T i þ γ’Ci þ εit :

ð2Þ

In equation 2, BIDit is participant i’s bid for the ANP t
(where t = Snus, Ariva, or Nicorette), αi is a random effects intercept term; Pi is a dummy variable that represents the product a person was bidding on and μ’ is the
associated coefficient; Li is a dummy variable that represents the ST product a person was offered to try and δ’
is the associated coefficient; Xi is a vector that represents
the demographic characteristics of participant i and β’ is
the associated coefficient vector; Ti is a vector that represents whether participant i accepted or rejected an opportunity to try an ANP and π’ is the associated
coefficient vector; Ci is a vector that represents the
demographic and tobacco-related characteristics of participant i and γ’ is the associated coefficient vector; and
εit is the error term.

Results
Table 1 presents the background and demographic characteristics of our sample. We had 258 participants across
the control group and three treatment groups. Sixty-five
percent of our sample identified themselves as white,
with 35 % identifying as non-white. Our sample was split
somewhat evenly between those under 30 years old, between 30 and 50 years old, and older than 50 years old.
For those who were over 50 years old, we found a statistically significant difference in the percentages across
treatments using a chi-squared test (p < 0.01). For all
other demographic characteristics, we found no statistically significant differences in demographic or background characteristics across any of the treatments.
Approximately two-thirds of the participants in the
Ariva (68 %) and Nicorette (64 %) treatments tried the
products, while fewer participants in the Camel Snus
group (44 %) tried snus. The differences between the
percentages of people who tried snus relative to Ariva or
Nicorette were statistically significant at the 1 % level
using a t test. Table 1 also shows how the characteristics
differed among those who accepted the offer to try the
product and those who were offered a free trial but
rejected it. Females were less likely to accept the free
trial of the ANP while those who had tried ST in the past
were more likely to accept the free trial of the ANP.4
Results from the probit model are shown in Table 2.
Those who were offered Nicorette and Ariva were more
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Table 2 Probit model examining the probability that a participant
in one of the three trial groups tried a product (N = 196)
Characteristics

Coefficient (standard
error in parentheses)
Intercept

−0.70
(0.57)

Product offered to
participant in trial

Nicorette

0.51b
(0.25)

Ariva

0.72b
(0.25)

Age

0.00
(0.01)

Income

0.11
(0.09)

Education

0.03
(0.10)
−0.19

Female

(0.23)
Black vs. White
Race/Ethnicity

−0.09
(0.29)

Other vs. white

−0.80a
(0.39)

South Carolina (vs. New York)
State

−0.40
(0.27)

Pennsylvania (vs. New York)

−0.21
(0.28)

Ever used smokeless tobacco

0.80b
(0.24)

Worried about their quality of life
because of smoking

0.10

Estimate of the cost of smokeless
tobacco products

−0.00

(0.22)

(0.01)

a

Statistically significant at the 0.05 level
b
Statistically significant at the 0.01 level

likely to try an ANP relative to those offered snus. Those
who considered themselves neither white nor black (i.e.,
in the other race category) were less likely to try an ST
product than whites. Those who had previously tried ST
products were more likely to accept the free product
trial.
The mean bids from the auctions are presented in
Table 3. The bid for snus was lower than the bid for
Ariva, which was lower than the bid for Nicorette, which
was lower than the bid for cigarettes. However, using
Bonferroni adjusted p values, differences between snus
and Nicorette are statistically significant (p < 0.01), and
the differences between cigarettes and all ANP are statistically significant (p < 0.01), but differences between

Ariva and snus and Ariva and Nicorette are not statistically significant at conventional levels (p = 0.129 and
0.315). The bid for snus among participants in the group
that was offered Nicorette was higher (p < 0.05) than
bids for snus in other treatments. There were no other
statistically significant differences in the unconditional
results based on which treatment participants were
placed.
To further examine the interaction between product
trials and product demand, we examine the bids for the
ST products for those who accepted and those who refused the product trial. These results are shown in
Table 4. The difference in bids for snus is lower for those
who accepted the trial at the 5 % level using a 2-sided t
test.
Results for the random effects regression are shown in
Table 5. Participants bid more for Ariva and Nicorette
than for snus. Those who were offered and rejected
Nicorette bid more for the ST products than others, and
the results were statistically significant in two of the
three models. We found no other impact of accepting or
rejecting a product trial on bid prices. Those who had a
higher estimate of the store price for ANP placed higher
bids for the ANP in the auction. The effect was statistically significant (p < 0.05) but small. For every US$1 increase in estimated store prices, participants bid
US$0.02 more for the ST product. We also find that
participants who bid higher for cigarettes also bid
higher for ST products. For every US$1 increase in a bid
for cigarettes, participants bid US$0.40 more for ST
products.
For a sensitivity analysis, we examined an alternative
view of demand—whether the participant placed a nonzero bid for the ANP. The results were similar: for snus,
those who tried snus were more likely to place a positive
bid. However, we found no evidence that product trials
of Ariva or Nicorette were more likely to bid a positive
amount for those products. Those results are available
from the authors upon request.

Discussion and conclusion
While product trials (e.g., free samples) have been utilized by the tobacco industry as a potential way to increase demand, we found evidence that trial mattered
for snus, but not other ANP: smokers who were willing
to try snus had a higher demand for snus, as assessed by
their bids. Indeed, while a majority of participants declined to try snus, the minority who tried it exhibited
greater demand, suggesting that experience of use may
be influential, that factors related to snus trial (e.g.,
comfort with placing tobacco vs. a more medicinal
appearing product in the mouth), or unmeasured differences between those who tried vs. did not try snus, were
likely to cause higher demand. For other products, the
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Table 3 Mean bids across treatment groups
Bid Snus

Bid Nicorette

Bid Ariva

Bid Cigarettes

Overalla (N = 258)

Control (N = 62)

Snus trial (N = 64)

Nicorette trial (N = 67)

Ariva trial (N = 65)

US$1.00

US$0.72

US$0.60

US$1.55b

US$1.13

(1.86)

(1.12)

(0.98)

(1.53)

(1.90)

US$1.87

US$2.04

US$1.54

US$1.87

US$2.03

(2.62)

(2.23)

(2.23)

(3.13)

(2.78)

US$1.40

US$1.44

US$0.91

US$1.78

US$1.47

(1.92)

(1.42)

(1.42)

(2.11)

(2.42)

US$4.06

US$4.09

US$3.30

US$4.16

US$4.76

(2.34)

(1.84)

(1.89)

(4.09)

(2.44)

(Standard deviations in parentheses)
Difference in bids for those who tried snus vs. those who chose not to try snus is statistically significant at the 5 % level
a
Differences in bids across all four products are statistically significant at the 5 % level using a 2-sided t test
b
Differences in bids for snus in the group that received the snus trial and those that received the Nicorette trial are statistically significant at the 5 % level using a
2-sided t test

willingness to sample the product was not correlated
with demand.
We found modest evidence that those who were offered but rejected the opportunity to try Nicorette bid
more for ST products. This provides some evidence that
there is a subset of smokers who may view Nicorette as
substantially different from other products that were
auctioned, perhaps reflecting a greater familiarity with
Nicorette, due to its having been on the market (as a
cessation aid) for a longer period of time. Those who
perceived a higher retail price bid more for the products,
suggesting that knowledge of outside prices influence
bids.
Further work is needed to understand the factors that
influence uptake and continued use of potentially reduced risk tobacco products. Some evidence suggests
that e-cigarettes, for example, are more appealing to
smokers than ST or nicotine replacement products [28].
Indeed, e-cigarettes appear to approximate the sensory
experience and bolus of nicotine that comes with smoking conventional cigarettes compared to consuming the
ANP examined in this study. Hence, trial of e-cigarettes
may be more likely to influence demand. Given the rapid
increase in e-cigarette use [29] future research should
examine whether product trials for e-cigarettes augment
demand.
This study is subject to some limitations. First, because
participants were not required to try the products, we
cannot rule out self-selection bias in the impact of free

trials on demand. That said, we only found evidence that
males (vs. females) and those who previously tried ST
products were more likely to accept the free trial. Second, we did not have sufficient sample size to randomize
the presentation order, and we appear to see an impact
based on ordering. That said, many studies have found
differences in bids across alternative products or labels
regardless of ordering. Third, participants were assigned
to try only one of the three products offered, so we cannot directly compare the impact of trials on demand
within subjects across products. Furthermore, experimental auctions in a controlled setting may not adequately represent what happens in the real world.
However, there are some consistency checks that make
us believe that our experimental auction captured what
would occur in the market. Our finding of relatively
lower demand for ANP vs. conventional cigarettes is
consistent with the relatively low demand found for
these products on the market [5, 10, 25, 28].
Those who accept a trial of ANP are showing that they
view the product as worth trying for free. In this regard,
it seems logical to expect that free trials would be correlated with higher demand, and indeed, might lead to
higher demand for ANP. However, we do not find widespread evidence of this. We only find that the willingness to try snus is positively correlated with demand.
For Nicorette and Ariva, free trial did not appear to increase demand. Given the debate over the potential for
ANP to reduce the harm from smoking, these results are

Table 4 Differences in bids for those who tried and did not try the ST products

N
Bid

Accepted snus trial:
bid for snus

Rejected snus trial:
bid for snus

Accepted Nicorette trial:
bid for Nicorette

Rejected Nicorette trial:
bid for Nicorette

Accepted ariva trial:
bid for ariva

Rejected ariva trial:
bid for ariva

28

36

43

24

44

21

0.93

0.34

1.43

2.66

1.58

1.26

(1.10)

(0.80)

(1.43)

(4.60)

(2.44)

(2.42)

a

(Standard deviations in parentheses)
a
Difference in bids for those who tried snus vs. those who chose not to try snus is statistically significant at the 5 % level
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Table 5 Random effects regression-dependent variable is bid on ST product (N = 258)
Characteristics
Product bid upon

Intercept
Nicorette
Ariva

In treatment where offered, but
rejected opportunity to take a
trial, relative to control group

Offered but rejected Snus

Offered but rejected Nicorette

Model 3

−1.60

−1.20

(0.71)+

(0.72)

(0.72)

0.89***

0.89***

0.89***

(0.13)

(0.13)

(0.13)

0.35***

0.35***

0.37***

(0.13)

(0.13)

(0.13)

−0.54

−0.06

−0.13

(0.39)

(0.35)

(0.35)

0.95**

0.87**

0.50

(0.46)

(0.41)

(0.40)

0.05

0.01

(0.46)

(0.41)

(0.40)

Tried Snus

−0.07

0.11

0.08

(0.42)

(0.38)

(0.37)

Tried Nicorette

0.20

0.27

0.23

(0.38)

(0.34)

(0.33)

0.18

−0.04

−0.06

(0.38)

(0.34)

(0.33)

−0.00

0.01

0.00

Tried Ariva

Age

Model 2

0.97

−0.08

Offered but rejected Ariva

In treatment where offered, and
accepted opportunity to take a
trial, relative to control group

Model 1

(0.01)

(0.01)

(0.01)

Income

−0.09

−0.08

−0.06

(0.10)

(0.09)

(0.09)

Education

0.12

−0.08

0.15

(0.11)

(0.09)

(0.10)

Female

Race/Ethnicity

0.15

0.14

0.11

(0.28)

(0.25)

(0.24)

Black vs. white

0.16

0.03

−0.01

(0.32)

(0.28)

(0.29)

0.57

0.05

0.13

(0.48)

(0.43)

(0.42)

−0.82

0.09

0.03

(0.31)

(0.29)

(0.30)

Other vs. white

State

South Carolina (vs. New York)
Pennsylvania (vs. New York)

Ever used smokeless tobacco

Worried about their quality of life because of smoking

Estimate of the cost of smokeless tobacco products

Bid for cigarettes

Participant preferred menthol cigarettes

−1.04***

−0.87***

−0.84***

(0.32)

(0.29)

(0.28)

0.10

0.09

0.04

(0.29)

(0.26)

(0.25)

−0.01

0.06

−0.01

(0.24)

(0.22)

(0.21)

0.02**

0.02***

0.02***

(0.01)

(0.01)

(0.01)

0.40***

0.38***

(0.05)

(0.05)
−0.06
(0.23)

**Statistically significant at the 0.05 level
***Statistically significant at the 0.01 level
+Robust standard errors are reported in parentheses
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important in understanding the impact of free trial offers
on adoption of ANP as a strategy to reduce harm from
tobacco use.

Endnotes
1
Nicorette is not a smokeless tobacco product, but rather an FDA-approved smoking cessation medication.
For ease of exposition, however, when we discuss “ST
products”, we are referring collectively to Ariva and
Snus, and when we discuss “alternative nicotine products (ANP)”, we are referring to all three products.
2
Ideally, we could have presented each smoker with an
opportunity to bid on his or her favorite brand. However, logistically (and for budgetary reasons) that would
have been difficult, as we would have had to have hundreds of different packs of cigarettes ready to sell in the
auction to be ready for all possible combinations of participant cigarette preferences.
3
This differs from a closed tender because there is no
negotiation. Further, a standard definition of an auction
involves collecting bids from participants and selling the
product or products to the highest bidder or bidders.
4
The order of product presentation across sessions
was fixed (i.e., not randomized) because we did not have
enough sessions to properly randomize the presentation
order. We first had participants bid on snus, then Ariva,
then Nicorette, and their last bid was for cigarettes. The
mean bids, coincidentally, increased on each subsequent
product. That said, bids change because of product attributes, not rounds. While some ordering effects could
occur (particularly because of framing), studies that have
varied the products across rounds have found that the
product characteristics tend to be the primary cause of
differences in bids. For example, Huffman et al. [30]
found that bids for GM-labeled food products were
lower than plain-labeled food products, regardless of
whether the first set of bids were on the plain-labeled or
GM-labeled foods. Another example is Thrasher et al.
[19] which did find a small difference based on ordering,
but found that bids for cigarettes with graphic pictorial
labels were lower than cigarettes with only a text warning, regardless of the ordering.
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